Technology evaluation: LErafAON, NeoPharm.

Article Details

Citation
Copy to clipboard

Moreira JN, Simoes S

Technology evaluation: LErafAON, NeoPharm.

Curr Opin Mol Ther. 2003 Oct;5(5):547-52.

PubMed ID
14601525 [ View in PubMed
]
Abstract

NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

DrugBank Data that Cites this Article

Drugs